Wall Street Isn't Talking About High-Yield Medtronic Stock -- Here's Why It Should Be
Medtronic (MDT) has undergone strategic shifts, exiting less profitable businesses and investing in new technology, leading to its highest annual revenue growth in a decade. Q1 fiscal 2027 saw a 13.7% revenue increase and earnings above guidance, prompting raised full-year forecasts. The stock has risen 15% in three months but remains 30% below its 2021 high, offering a high dividend yield.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise could re‑price the stock, attracting both growth and income investors.
Market read
First‑time earnings surprise for a high‑yield, large‑cap med‑tech stock.
What to watch
Potential competitive pressure from Intuitive Surgical and macro‑economic headwinds.
Background
Medtronic, a large diversified medical‑device maker, has historically been overlooked due to its size and dividend focus.
Ticker impact
Medtronic reported 13.7% revenue growth in Q1 FY2027 and raised full-year guidance after the quarter.
Potential price appreciation of 5‑10% over the next weeks.
Revenue growth exceeds expectations and management confidence is reflected in higher guidance, indicating improved fundamentals.
Market effects
Positive momentum may lift the broader medical‑device sector.
U.S. healthcare stocks could see modest gains.
Limited to investors focused on med‑tech and dividend yields.
Counterpoint
Yield‑focused investors may still be wary of valuation despite growth.
Key entities
- CompanyMedtronic
World’s largest medical‑device manufacturer.
